<DOC>
	<DOCNO>NCT00494312</DOCNO>
	<brief_summary>The purpose study determine liver safety pioglitazone , daily ( QD ) , versus glyburide take metformin insulin .</brief_summary>
	<brief_title>Safety Study Pioglitazone Compared To Glyburide Liver Function</brief_title>
	<detailed_description>Type 2 diabetes generally arise initial state insulin resistance coincides gradual decline insulin secretion due beta-cell dysfunction . Together , factor contribute impaired glucose tolerance eventually hyperglycemia . Thiazolidinediones selective agonist nuclear receptor peroxisomal proliferator-activated receptor gamma . These receptor find tissue insulin action include adipose tissue , skeletal muscle liver . Thiazolidinediones reduce insulin resistance enhance insulin sensitivity adipose tissue , muscle cell hepatic cell without directly affect insulin secretion . These effect improve glycemic control result reduce level circulate insulin . Pioglitazone thiazolidinedione develop Takeda Chemical Industries , Ltd. , depend presence insulin mechanism action . Glyburide oral antidiabetic agent sulfonylurea class , impact glycemic control stimulate pancreas release insulin , effect dependent upon beta-cells pancreatic islet . Elevated level hepatic enzyme , hepatocellular inflammation , viral susceptibility know occur increase frequency individual type 2 diabetes mellitus regardless type antidiabetic therapy use . Subject approval pioglitazone , Food Drug Administration request 3-year outcome study evaluate occurrence serious liver disease subject treat pioglitazone . The present study design fulfill phase 4 , postmarketing commitment Food Drug Administration , pursuant demonstrate long-term hepatic safety pioglitazone . This study design determine whether pioglitazone associate difference incidence elevate level alanine aminotransferase , marker hepatocellular inflammation injury , compare glyburide . Glyburide use treatment patient type 2 diabetes mellitus ; use study comparator provide basis evaluate whether pioglitazone associate increase risk hepatocellular inflammation injury .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Pioglitazone</mesh_term>
	<mesh_term>Glyburide</mesh_term>
	<criteria>Inclusion Criteria Females childbearing potential sexually active must agree use adequate contraception , neither pregnant lactating Screening throughout duration study Diagnosis type 2 ( noninsulin dependent ) diabetes mellitus define diagnostic criterion American Diabetes Association currently take glyburide , glipizide , glimepiride , metformin alone , glyburide , glipizide , glimepiride combination metformin Glycosylated hemoglobin level great equal 7.0 % Fasting Cpeptide level great equal 0.7 ng/mL . Type 1 ( insulindependent ) diabetes mellitus . Prior exposure thiazolidinedione , except subject discontinue use troglitazone March April 2000 , provide experience adverse effect take thiazolidinediones . Participating another investigational study participate investigational trial within precede 2 month . History ketoacidosis . The subject significant diabetic nephropathy , define serum creatinine level great equal 1.5 mg/dL men great equal 1.4 mg/dL woman , urinary protein excretion great equal 2 plus measured Combistix ( equivalent ) method , except subject proteinuria eligible repeat test within 2 week indicate proteinuria resolve . Anemia hemoglobin level less than12 g/dL men less than10 g/dL woman . The subject history drug alcohol abuse within precede 2 year . The subject diastolic blood pressure great than100 mm Hg systolic blood pressure great than180 mm Hg . The subject evidence ongoing cardiac rhythm disturbance , delay QT wave , seconddegree atrioventricular heart block . Uncomplicated firstdegree atrioventricular block allow . Significant cardiovascular disease include , limited , New York Heart Association Functional ( Cardiac ) Classification III IV . History myocardial infarction , acute cardiovascular event , cerebrovascular accident within precede 6 month . Previous history cancer remission least 5 year administration first dose study drug . Except , basal cell Stage I squamous cell carcinoma . The subject BMI le 20 great 48 ( calculate weight [ kg ] /height [ m2 ] ) . Alanine aminotransferase level great equal 2.5time upper limit normal history liver disease , jaundice , hepatitis , biliary tract disease ( except uncomplicated treat gall stone either lithotomy cholecystectomy ) . Unwilling unable comply protocol attend schedule appointment . Unable understand verbal and/or write English language certify translation inform consent available . Evidence acute unstable chronic pulmonary disease , chest xray available , unexplained pulmonary lesion . Is required take continue take disallow medication , prescription medication , herbal treatment overthe counter medication may interfere evaluation study medication , include : Antidiabetic agent study drug companion medication ( metformin insulin ) . Weight loss agent , include pharmaceutical overthecounter brand . Continuous ( great 2 week ) steroid therapy expect recurrent steroid therapy , include injectable , inhaled , topical , oral steroid formulation . Niacin therapy . Chronic condition recurrent use glucocorticoid could expect Any serious disease condition screen randomization might affect life expectancy make difficult successfully manage follow subject accord protocol .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>February 2012</verification_date>
	<keyword>Glucose Metabolism Disorder</keyword>
	<keyword>Dysmetabolic Syndrome</keyword>
	<keyword>Type II Diabetes</keyword>
	<keyword>Diabetes Mellitus</keyword>
	<keyword>Lipoatrophic</keyword>
	<keyword>Dyslipidemia</keyword>
	<keyword>Liver</keyword>
	<keyword>Drug Therapy</keyword>
</DOC>